PNC-27

PNC-27 combines residues 12-26 of the p53 transactivation domain with the penetratin sequence from the Antennapedia homeodomain. Research has characterized its binding to HDM-2 presented in the plasma membrane of cancer cells, a target reported to be largely absent from the membranes of normal cells.

Structural work describes the peptide adopting an HDM-2-binding conformation, with downstream transmembrane pore formation and necrotic lysis rather than apoptosis. Studies span leukemia, cervical, and pancreatic cancer models.

PNC-27 emerged from research on anticancer peptides derived from the ras-p21 and p53 proteins, in which short functional domains were fused to cell-penetrating sequences.

Subsequent work identified membrane-bound HDM-2 as the selectivity determinant and characterized the membrane-pore mechanism now described as "poptosis".

Research into PNC-27 focuses on selective interaction with membrane-bound HDM-2 and transmembrane pore formation in tumour cells. Frameworks evaluate conformational binding, membrane selectivity, necrotic versus apoptotic cell death, and mitochondrial membrane effects under controlled in vitro conditions.

• Membrane-bound HDM-2 targeting models
• Cell-penetrating peptide chimera design
• Transmembrane pore formation and necrosis
• Selective tumour-cell cytotoxicity research